CBDNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q4 and FY 2020 Financial, Operational Report
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has announced its fourth-quarter and full-year numbers for the period ended Dec. 31, 2020. In the report, Willow noted that it had filed a short form base shelf prospectus that allowed the company to make offerings of securities of up to an aggregate of $50 million. The company also completed an overnight marketed public offering for gross proceeds of $11.5 million, which was upsized by $2.0 million and included the exercise of a 15% overallotment. In addition, Willow inked a deal with…